id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
9260733_2 | We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[119]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"started on clozapine\"]], \"start\": [[131]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[142]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"polyserositis (pericardial effusion, pleural effusion, and pericarditis)\"]], \"start\": [[46]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[22]], \"entity_id\": [\"T16\"]}}"
}
]
}
] |
8053440_5 | Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"ampicillin\"]], \"start\": [[34]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[34]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"Three years later\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"cholestatic hepatitis with cholestasis and duct paucity on rebiopsy\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
8071504_5 | METHODS: A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[65]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[9]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"9-month course of treatment with ethambutol and isoniazid\"]], \"start\": [[73]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"pulmonary tuberculosis\"]], \"start\": [[135]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"9-month\"]], \"start\": [[73]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"ethambutol\"], [\"isoniazid\"]], \"start\": [[106], [121]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[117]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"ethambutol\"], [\"isoniazid\"]], \"start\": [[106], [121]], \"entity_id\": [\"T14\", \"T15\"]}}]}, \"Effect\": {\"text\": [[\"permanent vision loss\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
16239768_2 | The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[74]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"urinary incontinence (UI)\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"venlafaxine\"]], \"start\": [[104]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"venlafaxine\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
8651254_3 | The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"accelerated\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"M-CSF\"]], \"start\": [[35]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"M-CSF\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[4]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
14996269_2 | We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious hypernatraemia, that has never been reported before in preterm infants. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[85]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Kayexalate\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"hyperkalaemia\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Kayexalate\"]], \"start\": [[69]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"two ELBW infants affected by hyperkalaemia\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"infants\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"ELBW\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"serious hypernatraemia\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"serious\"]], \"start\": [[95]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
8384030_2 | DISCUSSION: Electrolyte disorders associated with foscarnet are reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Electrolyte disorders\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"foscarnet\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9232614_3 | We report two cases that developed acute myeloid leukaemia (AML) during tamoxifen therapy for breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute myeloid leukaemia (AML)\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"tamoxifen therapy for breast cancer\"]], \"start\": [[72]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[94]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[10]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15261876_1 | Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received levodopa and anti-cholinergic drugs and whose head had become almost completely bald. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"become\"]], \"start\": [[141]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 72-year-old man with advanced Parkinson's disease (PD)\"]], \"start\": [[16]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"72-year-old\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"levodopa and anti-cholinergic drugs\"]], \"start\": [[86]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"advanced Parkinson's disease (PD)\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"levodopa\"], [\"anti-cholinergic drugs\"]], \"start\": [[86], [99]], \"entity_id\": [\"T10\", \"T11\"]}}, \"Effect\": {\"text\": [[\"completely bald\"]], \"start\": [[155]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18633310_2 | The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"hallucinations, agitation, vomiting, tachycardia and seizures\"]], \"start\": [[24]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"ingestion of 1050 (48 mg/kg) of extended-release bupropion\"]], \"start\": [[92]], \"entity_id\": [\"T13\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[92]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"1050 (48 mg/kg)\"]], \"start\": [[105]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"bupropion\"]], \"start\": [[141]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
1440123_1 | This case report describes a 38-year-old male in whom SIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suspected\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"38-year-old male\", \"a seizure disorder\"]], \"start\": [[29, 124]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"38-year-old\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[41]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"Tegretol\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Tegretol\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"seizure\"]], \"start\": [[126]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"SIADH\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17199845_1 | However, cyclosporine dependency is associated with the risk of nephrotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cyclosporine dependency\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"nephrotoxicity\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
3335488_1 | The observations suggest that testicular swelling and pain are side effects of desipramine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effects\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"testicular swelling and pain\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"desipramine\"]], \"start\": [[79]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"desipramine\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11722307_3 | METHOD: We describe three case-reports concerning haematological adverse effects of quetiapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effects\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"haematological adverse effects\"]], \"start\": [[50]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"quetiapine\"]], \"start\": [[84]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[84]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1575118_1 | Typically, drug-induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurs\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"drug-induced neutropenia\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"a semisynthetic penicillin for two weeks or more\"]], \"start\": [[66]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"semisynthetic penicillin\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Duration\": {\"text\": [[\"two weeks\"]], \"start\": [[97]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2554727_5 | Peripheral nerve dysfunction is a potentially serious complication of high-dose cytosine arabinoside. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Peripheral nerve dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[80]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[80]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[70]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[34]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17444802_1 | Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increase\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"Tumor-volume increase\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"primary treatment with topical interferon alpha 2-beta\"]], \"start\": [[38]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"interferon alpha 2-beta\"]], \"start\": [[69]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[61]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"beginning\"]], \"start\": [[25]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"conjunctiva-cornea intraepithelial neoplasia\"]], \"start\": [[106]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"a case of conjunctiva-cornea intraepithelial neoplasia\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
18504683_1 | L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"posterior reversible encephalopathy syndrome\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"children\"]], \"start\": [[117]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[117]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9184269_3 | On the other hand, MTX-induced pneumonitis seems to be very rare in psoriatic arthritis (PsA). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[19]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"seems\"]], \"start\": [[43]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
3899068_1 | Ototoxicity as a result of cis-platinum administration is well documented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Ototoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cis-platinum administration\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cis-platinum\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9892272_1 | Massive subfascial hematoma after alteplase therapy for acute myocardial infarction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Massive subfascial hematoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"alteplase therapy\"]], \"start\": [[34]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"alteplase\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"acute myocardial infarction\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11881322_7 | We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"responsible\"]], \"start\": [[78]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[16]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"drug-induced vanishing bile duct syndrome\"]], \"start\": [[96]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[71]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
14998226_2 | A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[68]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[59]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[59]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"increased international normalized ratio (INR)\"]], \"start\": [[83]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"A 67-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"67-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T14\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"switched\"]], \"start\": [[181]], \"entity_id\": [\"T21\"]}, \"Treatment\": {\"text\": [[\"atorvastatin therapy was switched to fluvastatin\"]], \"start\": [[156]], \"entity_id\": [\"T22\"], \"Drug\": {\"text\": [[\"fluvastatin\"], [\"atorvastatin\"]], \"start\": [[193], [156]], \"entity_id\": [\"T17\", \"T16\"]}, \"Disorder\": {\"text\": [[\"bleeding\"]], \"start\": [[138]], \"entity_id\": [\"T19\"]}}}"
}
]
}
] |
1295628_4 | The cases of CBZ-induced SLE reported in the literature were reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"CBZ\"]], \"start\": [[13]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"CBZ\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"SLE\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19892516_1 | Ciprofloxacin-induced hemorrhagic vasculitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hemorrhagic vasculitis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8691927_4 | INTERPRETATION: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[119]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"high doses of fluticasone propionate\"]], \"start\": [[21]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"high doses\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"fluticasone propionate\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"growth may be retarded and adrenal suppression\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10614572_2 | To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"hypotension\"]], \"start\": [[58]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravenous valproate\"]], \"start\": [[86]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[98]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[86]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"status epilepticus\"]], \"start\": [[128]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"pediatric population\"]], \"start\": [[154]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[154]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8678015_3 | While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"albendazole\"]], \"start\": [[32]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"albendazole\"]], \"start\": [[32]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[45]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[45]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"worsening diarrhea with abdominal pain and fever\"]], \"start\": [[58]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
17655517_1 | Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome.\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
7538828_1 | Bone marrow aplasia and severe skin rash after a single low dose of methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Bone marrow aplasia and severe skin rash\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"a single low dose of methotrexate\"]], \"start\": [[47]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"single low dose\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[24]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
3124393_1 | A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo-Medrol, developed a spastic paraparesis at the lower limbs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[144]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A woman 38-year-old, suffering for about ten years from multiple sclerosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"38-year-old\"]], \"start\": [[8]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"repeated therapy cycles of intrathecal Depo-Medrol\"]], \"start\": [[92]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Depo-Medrol\"]], \"start\": [[131]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[56]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[119]], \"entity_id\": [\"T12\"]}, \"Freq\": {\"text\": [[\"repeated\"]], \"start\": [[92]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"a spastic paraparesis at the lower limbs\"]], \"start\": [[154]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8513656_10 | The efficacy of single-dose disulfiram as an inhibitor of human P450 2E1 suggests that this modality for manipulating clinical P450 2E1 activity may provide a useful probe for delineating P450 2E1 participation in human drug biotransformation or for the treatment of poisoning by P450 2E1-activated toxins. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[277]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"poisoning\"]], \"start\": [[267]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"P450 2E1-activated toxins\"]], \"start\": [[280]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"disulfiram\"], [\"P450 2E1-activated toxins\"]], \"start\": [[28], [280]], \"entity_id\": [\"T11\", \"T9\"]}, \"Dosage\": {\"text\": [[\"single-dose\"]], \"start\": [[16]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
3579660_2 | To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presenting\"]], \"start\": [[237]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"25 additional patients with Wilson's disease\"]], \"start\": [[168]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"25\"]], \"start\": [[168]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"neurologic disease\"]], \"start\": [[253]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[301]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[301]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"Wilson's disease\"]], \"start\": [[196]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
10779995_3 | The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[102]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"oral etoposide\"]], \"start\": [[120]], \"entity_id\": [\"T3\"], \"Time_elapsed\": {\"text\": [[\"18 months\"]], \"start\": [[92]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[120]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"etoposide\"]], \"start\": [[125]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"metastatic neuroblastoma\"]], \"start\": [[67]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"t-AML\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a child with metastatic neuroblastoma\"]], \"start\": [[54]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7781845_10 | Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti-malarial quinine analogues are discussed. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hypoglycaemia\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"mefloquine and some other anti-malarial quinine analogues\"]], \"start\": [[62]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"mefloquine\"], [\"quinine analogues\"]], \"start\": [[62], [102]], \"entity_id\": [\"T8\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"mefloquine\"], [\"quinine analogues\"]], \"start\": [[62], [102]], \"entity_id\": [\"T8\", \"T10\"]}}]}}"
}
]
}
] |
11414270_15 | Only nondepolarizing muscle relaxants should be used in patients who are at risk for mucositis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"nondepolarizing muscle relaxants\"]], \"start\": [[5]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nondepolarizing muscle relaxants\"]], \"start\": [[5]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"patients who are at risk for mucositis\"]], \"start\": [[56]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"mucositis\"]], \"start\": [[85]], \"entity_id\": [\"T12\"]}}, \"Speculated\": {\"text\": [[\"should\"]], \"start\": [[38]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
15685264_11 | CONCLUSION: A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"medication\"]], \"start\": [[140]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[155]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine medication\"]], \"start\": [[126]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"a spinal cord lesion\"]], \"start\": [[170]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"Dantrolene\"], [\"Oxybutynin\"], [\"Carbamazepine\"]], \"start\": [[59], [74], [126]], \"entity_id\": [\"T16\", \"T17\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[39]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"Dantrolene\"], [\"Oxybutynin\"]], \"start\": [[59], [74]], \"entity_id\": [\"T16\", \"T17\"]}}]}}"
}
]
}
] |
19307676_3 | We describe a 15-year-old female patient diagnosed with acute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[120]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 15-year-old female patient diagnosed with acute lymphoblastic leukemia\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"15-year-old\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"presenting with status epilepticus\"]], \"start\": [[85]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"receiving intrathecal methotrexate\"]], \"start\": [[126]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[136]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[148]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[56]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
3767790_1 | Duodenal ulceration: a complication of tolazoline therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"tolazoline\"]], \"start\": [[39]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"tolazoline\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Duodenal ulceration\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1747495_1 | Hepatic damage after danazol treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hepatic damage\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"danazol\"]], \"start\": [[21]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10461415_2 | Hepato-biliary abnormalities secondary to ceftriaxone use: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary to\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Hepato-biliary abnormalities\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ceftriaxone use\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
12243603_1 | Rhabdomyolysis with concurrent atorvastatin and diltiazem. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Rhabdomyolysis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"diltiazem\", \"atorvastatin\"]], \"start\": [[48, 31]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"atorvastatin\"], [\"diltiazem\"]], \"start\": [[31], [48]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concurrent\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"atorvastatin\"], [\"diltiazem\"]], \"start\": [[31], [48]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
7900744_1 | Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"syndrome\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"mannitol\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"mannitol\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"nephrotoxicity\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
8710040_1 | Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[8]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Uveitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"combination of rifabutin, clarithromycin and ethambutol\"]], \"start\": [[103]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"disseminated Mycobacterium avium-intracellulare complex infection\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"rifabutin\"], [\"clarithromycin\"], [\"ethambutol\"]], \"start\": [[118], [129], [148]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[103]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"rifabutin\"], [\"clarithromycin\"], [\"ethambutol\"]], \"start\": [[118], [129], [148]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}}]}}"
}
]
}
] |
16527771_2 | The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"visual loss\", \"neurotoxicity\"]], \"start\": [[4, 60]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenol\"]], \"start\": [[53]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"phenol\"]], \"start\": [[53]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16200540_1 | Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"augmentation of restless legs syndrome\"]], \"start\": [[66]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"levodopa\"]], \"start\": [[49]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"levodopa\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15752306_6 | These cases highlight the occurrence of livedo reticularis as an uncommon side-effect of interferon alpha treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side-effect\"]], \"start\": [[74]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"These cases\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"livedo reticularis\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"interferon alpha\"]], \"start\": [[89]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11399735_1 | So far, few cases of pulmonary side effects caused by ticlopidine have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"pulmonary side effects\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ticlopidine\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"few cases\"]], \"start\": [[8]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
21104646_1 | Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Abnormal\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Abnormal dexamethasone suppression tests\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[46]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Cushing's syndrome\"]], \"start\": [[88]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[46]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patient with suspected Cushing's syndrome\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[78]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
16109609_2 | Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"carcinoma\"]], \"start\": [[102]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"radiation recall reactions\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15266150_2 | Increased lash length, thickness, and pigmentation are well-documented side effects of prostaglandin analog glaucoma drops. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"are\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Increased lash length, thickness, and pigmentation\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"prostaglandin analog glaucoma drops\"]], \"start\": [[87]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"drops\"]], \"start\": [[117]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"prostaglandin analog\"]], \"start\": [[87]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"glaucoma\"]], \"start\": [[108]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
25957434_1 | Bullous Eruption Associated With Dihydropyridines With Cross Reactivity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Associated\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Dihydropyridines\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Dihydropyridines\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Bullous Eruption\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11020127_3 | Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"acted\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Ritonavir\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Ritonavir\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
17083900_1 | Acute generalized exanthematous pustulosis induced by nimesulide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute generalized exanthematous pustulosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nimesulide\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nimesulide\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11225532_1 | Quinine induced coagulopathy--a near fatal experience. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[8]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Quinine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Quinine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"coagulopathy--a near fatal experience\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[37]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
71813_1 | A 58-year-old man with rheumatoid arthritis developed lichen planus during treatment with gold. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"treatment with gold\"]], \"start\": [[75]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[90]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"lichen planus during\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 58-year-old man with rheumatoid arthritis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"58-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2347102_1 | Atenolol-induced pseudolymphoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[9]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Atenolol\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Atenolol\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pseudolymphoma\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
25407257_1 | First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"convulsive seizures\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"co-administration of valproic acid and tebipenem\"]], \"start\": [[67]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"valproic acid\"], [\"tebipenem\"]], \"start\": [[88], [106]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"co-administration\"]], \"start\": [[67]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"valproic acid\"], [\"tebipenem\"]], \"start\": [[88], [106]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
10755579_1 | Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Fluoxetine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Fluoxetine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"child with cytochrome P-450 2D6 genetic deficiency\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"cytochrome P-450 2D6 genetic deficiency\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"death\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
448845_1 | Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[36]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"Aplastic anemia and agranulocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"patients\", \"glaucoma\"]], \"start\": [[39, 72]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"methazolamide\"]], \"start\": [[54]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"methazolamide\"]], \"start\": [[54]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"glaucoma\"]], \"start\": [[72]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
15735923_3 | We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[80]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a 44-year-old woman\"]], \"start\": [[10]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"44-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[24]], \"entity_id\": [\"T14\"]}, \"Population\": {\"text\": [[\"a\"]], \"start\": [[10]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"t-MDS (refractory anemia with excess blasts)\"]], \"start\": [[35]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)\"]], \"start\": [[90]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"recurrent anaplastic astrocytoma\"]], \"start\": [[103]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"temozolomide\"]], \"start\": [[141]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
11332679_1 | An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[128]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"a combination of allopurinol and ketoconazole\"]], \"start\": [[141]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"allopurinol\"], [\"ketoconazole\"]], \"start\": [[158], [174]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[143]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"allopurinol\"], [\"ketoconazole\"]], \"start\": [[158], [174]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"pancreatitis\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"An infant\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8345435_2 | L-Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[90]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"valproic acid\"]], \"start\": [[106]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"valproic acid\"]], \"start\": [[106]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hepatotoxic effects\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[64]], \"entity_id\": [\"T3\"], \"value\": \"High\"}}"
},
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"recommended\"]], \"start\": [[37]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"L-Carnitine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"L-Carnitine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"fatal hepatotoxic effects\"]], \"start\": [[64]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
8641617_6 | The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin-based combination chemotherapy in ovarian cancer patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[98]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Clostridium difficile colitis\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cisplatin-based combination chemotherapy\"]], \"start\": [[114]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[142]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"ovarian cancer\"]], \"start\": [[158]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"ovarian cancer patients\"]], \"start\": [[158]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7854541_1 | Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"adjuvant therapy with levamisole\"]], \"start\": [[61]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"levamisole\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"malignant melanoma\"]], \"start\": [[98]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Cerebral demyelinating disease\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3558331_1 | Amoxapine-induced cognitive impairment in two patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Amoxapine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Amoxapine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"cognitive impairment\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
21881031_5 | Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15) were used prior to irinotecan administration in both patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[131]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15)\", \"irinotecan\"]], \"start\": [[0, 145]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Granisetron hydrochloride\"], [\"dexamethasone\"]], \"start\": [[0], [58]], \"entity_id\": [\"T11\", \"T15\"]}, \"Dosage\": {\"text\": [[\"3 mg\"], [\"13.2 mg\"], [\"6.6 mg\"]], \"start\": [[27], [73], [94]], \"entity_id\": [\"T12\", \"T16\", \"T18\"]}, \"Freq\": {\"text\": [[\"on day 1\"], [\"on days 1, 8, and 15\"], [\"on days 2, 3, 8, and 15\"]], \"start\": [[81], [32], [101]], \"entity_id\": [\"T17\", \"T13\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[54]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"dexamethasone\"], [\"Granisetron hydrochloride\"]], \"start\": [[58], [0]], \"entity_id\": [\"T15\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"both patients\"]], \"start\": [[174]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
6245286_3 | Visceral herpesvirus infections in leukemic patients receiving cytarabine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Visceral herpesvirus infections\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cytarabine\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cytarabine.\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"leukemic\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"leukemic patients\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
8678015_2 | Although a few case reports link metronidazole with the development of pseudomembranous colitis, albendazole has not been associated with the development of this condition. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"metronidazole\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"metronidazole\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pseudomembranous colitis\"]], \"start\": [[71]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11414270_13 | CONCLUSION: Oral mucositis is a frequent and potentially severe complication of cancer chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Oral mucositis\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"cancer chemotherapy\"]], \"start\": [[80]], \"entity_id\": [\"T7\"], \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[87]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[45]], \"entity_id\": [\"T9\"], \"value\": true}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[57]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
10431414_1 | One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"during heparin therapy\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"surgical operation to the knee\"]], \"start\": [[68]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"priapism\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"One case\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
12365708_5 | While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"amiodarone and digoxin\"]], \"start\": [[11]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"amiodarone\"], [\"digoxin\"]], \"start\": [[11], [26]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[22]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"amiodarone\"], [\"digoxin\"]], \"start\": [[11], [26]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"permanent visual changes\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
15543388_1 | AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a woman patient\"]], \"start\": [[25]], \"entity_id\": [\"T4\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"celiac disease\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C\"]], \"start\": [[76]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"pegylated interferon alpha-2a\"], [\"ribavirin\"]], \"start\": [[76], [110]], \"entity_id\": [\"T9\", \"T11\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[128]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[106]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"ribavirin\"], [\"pegylated interferon alpha-2a\"]], \"start\": [[110], [76]], \"entity_id\": [\"T11\", \"T9\"]}}]}}"
}
]
}
] |
11243427_2 | Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[88]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"5-FU\"]], \"start\": [[83]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"ectropion\"]], \"start\": [[96]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9660541_1 | In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[36]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"mitomycin C (MMC)\"]], \"start\": [[14]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"mitomycin C\"]], \"start\": [[14]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"cancer-associated hemolytic uremic syndrome\", \"hemolytic anemia, thrombocytopenia and progressive renal failure\"]], \"start\": [[43, 114]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"In rare cases\"]], \"start\": [[0]], \"entity_id\": [\"T18\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[32]], \"entity_id\": [\"T16\"], \"value\": true}}"
}
]
}
] |
16968538_1 | Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"oxaliplatin\"]], \"start\": [[52]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"oxaliplatin\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Hemolytic uremic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12699871_4 | Tacrolimus (FK506)-induced mutism after liver transplant. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Tacrolimus (FK506\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Tacrolimus\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"mutism\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17009081_4 | Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effect\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"proteinuria and nephrotic syndrome\"]], \"start\": [[7]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"IFN-beta-1b\"]], \"start\": [[70]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"IFN-beta-1b\"]], \"start\": [[70]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"MS\"]], \"start\": [[111]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"MS patients\"]], \"start\": [[111]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
2894766_1 | It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[37]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[37]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
1310879_2 | By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[249]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"platelet activation\"]], \"start\": [[257]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG)\"]], \"start\": [[92]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Fragmin\"], [\"Fraxiparin\"], [\"Clexane\"]], \"start\": [[130], [142], [209]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}}}"
}
]
}
] |
19357764_2 | DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead\"]], \"start\": [[73]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hyperlactatemia relapse\"]], \"start\": [[83]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"This case\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"zidovudine\"]], \"start\": [[46]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"zidovudine\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
9232614_1 | Acute leukaemia during tamoxifen therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Acute leukaemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"tamoxifen therapy\"]], \"start\": [[23]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1310879_3 | Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[8]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Heparin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Heparin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3970339_1 | A patient presented with a painful, oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"injected a solution of diamorphine and methylphenidate into his radial artery\"]], \"start\": [[69]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"injected\", \"into his radial artery\"]], \"start\": [[69, 124]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"diamorphine\"], [\"methylphenidate\"]], \"start\": [[92], [108]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[104]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"diamorphine\"], [\"methylphenidate\"]], \"start\": [[92], [108]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"painful, oedematous, cyanosed hand\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9509511_2 | We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"vincristine and actinomycin D\"]], \"start\": [[17]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"vincristine\"], [\"actinomycin D\"]], \"start\": [[17], [33]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"vincristine\"], [\"actinomycin D\"]], \"start\": [[17], [33]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[83]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
6702890_2 | Pure red cell aplasia associated with fenoprofen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Pure red cell aplasia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fenoprofen\"]], \"start\": [[38]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fenoprofen\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16239768_1 | A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with venlafaxine 75 mg/day. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 56-year-old white woman with a diagnosis of reactive depression\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"56-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"severe UI\"]], \"start\": [[76]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"30 days' treatment with venlafaxine 75 mg/day.\"]], \"start\": [[94]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"reactive depression\"]], \"start\": [[46]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"30 days\"]], \"start\": [[94]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"venlafaxine\"]], \"start\": [[118]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"75 mg/day\"]], \"start\": [[130]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
10891991_5 | PATIENTS: Three patients developed a reproductive endocrine disorder during treatment with valproate. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Three patients\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"reproductive endocrine disorder\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[91]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[91]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10410183_2 | OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[78]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[94]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[94]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"marked elevation of serum creatine kinase\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8641617_5 | Severe C. difficile colitis occurred in 2 patients (6.1%) after receiving cisplatin-based combination chemotherapy for ovarian malignancies. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Severe C. difficile colitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"2 patients (6.1%)\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"2\"], [\"(6.1%)\"]], \"start\": [[40], [51]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Treatment\": {\"text\": [[\"cisplatin-based combination chemotherapy\"]], \"start\": [[74]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"ovarian malignancies\"]], \"start\": [[119]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[102]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
3430507_6 | A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 56-year-old woman with scleroderma\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"56-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis\"]], \"start\": [[47]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"27 months of D-penicillamine therapy and a cumulative dose of 1,200 g\"]], \"start\": [[145]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"scleroderma\"]], \"start\": [[25]], \"entity_id\": [\"T13\"]}, \"Time_elapsed\": {\"text\": [[\"27 months\"]], \"start\": [[145]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[158]], \"entity_id\": [\"T15\"]}, \"Dosage\": {\"text\": [[\"1,200 g\"]], \"start\": [[207]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
9831311_2 | High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"leads\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"High-dose phosphate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"hypophosphatemic osteomalacia\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"phosphate\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"High-dose\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hypokalemia\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2212262_2 | We report a patient who developed heparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[70]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"heparin\", \"continuous arteriovenous haemofiltration\"]], \"start\": [[34, 77]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"heparin associated thrombocytopenia\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17133571_2 | We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"fulminant hepatitis\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"nevirapine\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nevirapine\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7900744_5 | The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"ARF\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"mannitol infusion\"]], \"start\": [[56]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"mannitol\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
15190230_2 | In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[135]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the first dose of pegylated interferon alpha.\"]], \"start\": [[141]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"chronic hepatitis B\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"first dose\"]], \"start\": [[145]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"pegylated interferon alpha\"]], \"start\": [[159]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute dystonia\"]], \"start\": [[115]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case with chronic hepatitis B\"]], \"start\": [[68]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"a\"]], \"start\": [[68]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[115]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
15266150_3 | Trichiasis associated with prostaglandin analog use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Trichiasis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"prostaglandin analog\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"prostaglandin analog\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2937155_2 | The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"vancomycin\"]], \"start\": [[130]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[130]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"drug-induced vasculitis or lupus-like syndrome\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[4]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
17381671_8 | Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[57]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"fentanyl and other phenylpiperidine opioids\", \"treated with SSRIs\"]], \"start\": [[126, 182]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"fentanyl\"], [\"phenylpiperidine opioids\"], [\"SSRIs\"]], \"start\": [[126], [145], [195]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[182]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"phenylpiperidine opioids\"], [\"fentanyl\"], [\"SSRIs\"]], \"start\": [[145], [126], [195]], \"entity_id\": [\"T14\", \"T13\", \"T15\"]}}]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[173]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[48]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
16196187_1 | Acute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute myocardial ischemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"accidental intravenous administration of epinephrine in high concentration\"]], \"start\": [[36]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intravenous administration\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"epinephrine\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"high concentration\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |